αS1-Casein-Loaded Proteo-liposomes as Potential Inhibitors in Amyloid Fibrillogenesis: In Vivo Effects on a C. elegans Model of Alzheimer’s Disease-Reference-Cited by-同舟云学术

α_S1-Casein-Loaded Proteo-liposomes as Potential Inhibitors in Amyloid Fibrillogenesis: In Vivo Effects on a C. elegans Model of Alzheimer’s Disease

Published:2023-10-17 Issue:21 Volume:14 Page:3894-3904
ISSN:1948-7193
Container-title:ACS Chemical Neuroscience
language:en
Short-container-title:ACS Chem. Neurosci.

Author:

Paterna Angela¹,Santonicola Pamela²³^ORCID,Di Prima Giulia⁴,Rao Estella¹,Raccosta Samuele¹,Zampi Giuseppina²,Russo Claudio³⁵,Moran Oscar⁶,Manno Mauro¹^ORCID,Di Schiavi Elia²,Librizzi Fabio¹,Carrotta Rita¹^ORCID

Affiliation:

1. Institute of Biophysics, National Research Council, Division of Palermo, Via Ugo La Malfa 153, 90146 Palermo, Italy

2. Institute of Biosciences and Bioresources, Division of Napoli, Via Pietro Castellino 111, 80131 Napoli, Italy

3. Department of Medicine and Health Sciences, University of Molise, 86100 Campobasso, Italy

4. Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, 90123 Palermo, Italy

5. Consorzio Interuniversitario in Ingegneria e Medicina (COIIM), Via F. De Sanctis, 86100 Campobasso, Italy

6. Institute of Biophysics, National Research Council, Division of Genova, Via De Marini 6, 16149 Genova, Italy

Publisher

American Chemical Society (ACS)

Subject

Cell Biology,Cognitive Neuroscience,Physiology,Biochemistry,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acschemneuro.3c00239

Reference62 articles.

1. Drug development in Alzheimer’s disease: the path to 2025

2. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019

3. FDA approval for Biogen’s aducanumab sparks Alzheimer disease firestorm

4. Open Peer Commentary to “Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019”

5. Lecanemab in Early Alzheimer’s Disease

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revolutionizing Alzheimer's treatment: Harnessing human serum albumin for targeted drug delivery and therapy advancements;Ageing Research Reviews;2024-08